| 摘要: |
| 毛霉病是一种致死率高的侵袭性真菌感染,两性霉素B(AmB)作为核心治疗药物,对毛霉菌具有显著的体外抗菌活性,其单药治疗的疗效与安全性已获多项临床试验和回顾性研究证实。有研究提示AmB与唑类、棘白菌素类药物存在协同抗菌作用,以及局部联合静脉给药可优化疗效,但均为病例报告或小样本回顾性研究,尚缺乏高级别循证支持。本文综述了毛霉病的流行病学特征、AmB体外抗菌活性及其临床应用进展,以期为优化AmB治疗策略提供思路及方向。 |
| 关键词: 两性霉素B 毛霉病 侵袭性真菌感染 |
| DOI:10.13506/j.cnki.jpr.2026.01.012 |
| 基金项目:江苏省药学会-奥赛康医院药学基金科研项目(No.A202105);南京药学会-常州四药医院药学科研基金(No.2021YX008) |
|
出版日期:2026-01-26
|
|
| Application and research progress of Amphotericin B for the treatment of mucormycosis |
| KAN Min,WU Yuanyuan,SHAO Hua |
| (Department of Pharmacy,Zhongda Hospital, Southeast University, Nanjing 210009, China) |
| Abstract: |
| Mucormycosis is an invasive fungal infection with high mortality. Amphotericin B (AmB), as the cornerstone therapeutic drug, demonstrates potent in vitro antifungal activity against Mucorales. The efficacy and safety as monotherapy have been confirmed by multiple clinical trials and retrospective studies. Emerging studies suggest potential synergistic effects between AmB and azoles or echinocandins, as well as enhanced therapeutic outcomes through combined local and intravenous administration. However, these findings are currently limited to case reports or small-scale retrospective studies, lacking high-level evidence-based support. This article reviews the epidemiological characteristics of mucormycosis, the in vitro antifungal activity of AmB, and the progress of its clinical applications, aiming to provide insights and future directions for optimizing AmB-based treatment strategies. |
| Key words: Amphotericin B Mucormycosis Invasive fungal infection |